126 related articles for article (PubMed ID: 2985163)
1. In vivo interaction of prostacyclin with an inhibitor of cyclic nucleotide phosphodiesterase, HL 725.
Darius H; Lefer AM; Leprán I; Smith JB
Br J Pharmacol; 1985 Mar; 84(3):735-41. PubMed ID: 2985163
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the effects of a thromboxane synthase inhibitor or prostacyclin in combination with a phosphodiesterase inhibitor for prevention of experimental thrombosis and sudden death in rabbits.
Smith EF; Egan JW
J Pharmacol Exp Ther; 1987 Jun; 241(3):855-60. PubMed ID: 3298621
[TBL] [Abstract][Full Text] [Related]
3. HL 725, an extremely potent inhibitor of platelet phosphodiesterase and induced platelet aggregation in vitro.
Ruppert D; Weithmann KU
Life Sci; 1982 Nov; 31(19):2037-43. PubMed ID: 6294426
[TBL] [Abstract][Full Text] [Related]
4. Cyclic nucleotide phosphodiesterase inhibitors prevent aggregation of human platelets by raising cyclic AMP and reducing cytoplasmic free calcium mobilization.
Lanza F; Beretz A; Stierlé A; Corre G; Cazenave JP
Thromb Res; 1987 Mar; 45(5):477-84. PubMed ID: 3035738
[TBL] [Abstract][Full Text] [Related]
5. Refractoriness of platelets to prostaglandins after infusion in rabbits.
Bertelé V; Stemerman M; Schafer A; Adelman B; Smith M; Fuhro R; Salzman E
J Lab Clin Med; 1985 Nov; 106(5):551-61. PubMed ID: 2997353
[TBL] [Abstract][Full Text] [Related]
6. The effects of continuous infusions of prostacyclin-Na (epoprostenol-sodium) on platelet counts, ADP-induced aggregation, and cyclic AMP levels in normal volunteers.
Reele SB; Miller OV; Spillers C; Gorman RR
Prostaglandins; 1983 Aug; 26(2):287-302. PubMed ID: 6316420
[TBL] [Abstract][Full Text] [Related]
7. The orally active thia-imino-prostacyclin Hoe 892: antiaggregatory and cardiovascular activities.
Schölkens BA; Gehring D; Jung W
Prostaglandins Leukot Med; 1983 Mar; 10(3):231-56. PubMed ID: 6405394
[TBL] [Abstract][Full Text] [Related]
8. Effect of prostacyclin (epoprostenol) on the aggregation of human platelets in whole blood in vitro.
Saniabadi AR; Lowe GD; Belch JJ; Barbenel JC; Forbes CD
Haemostasis; 1984; 14(6):487-94. PubMed ID: 6442909
[TBL] [Abstract][Full Text] [Related]
9. Intravenous administration of prostacyclin in rabbits: elimination kinetics and blood pressure response.
Skrinska VA; Lucas FV; Chisolm GM; Hesse BL
J Lab Clin Med; 1986 Mar; 107(3):187-93. PubMed ID: 3512745
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of the antiaggregatory activity of prostacyclin by propranolol in human platelets.
Callahan KS; Johnson AR; Campbell WB
Circulation; 1985 Jun; 71(6):1237-46. PubMed ID: 2986877
[TBL] [Abstract][Full Text] [Related]
11. Role of plasma adenosine in the antiplatelet action of HL 725, a potent inhibitor of cAMP phosphodiesterase: species differences.
Agarwal KC; Buckley RS; Parks RE
Thromb Res; 1987 Jul; 47(2):191-200. PubMed ID: 2821650
[TBL] [Abstract][Full Text] [Related]
12. Systemic and transcardiac platelet activity in acute myocardial infarction in man: resistance to prostacyclin.
Mueller HS; Rao PS; Greenberg MA; Buttrick PM; Sussman II; Levite HA; Grose RM; Perez-Davila V; Strain JE; Spaet TH
Circulation; 1985 Dec; 72(6):1336-45. PubMed ID: 2933181
[TBL] [Abstract][Full Text] [Related]
13. A chemically stable analogue, 9 beta-methyl carbacyclin, with similar effects to epoprostenol (prostacyclin, PGI2) in man.
O'Grady J; Hedges A; Whittle BJ; Al-Sinawi LA; Mekki QA; Burke C; Moody SG; Moti MJ; Hassan S
Br J Clin Pharmacol; 1984 Dec; 18(6):921-33. PubMed ID: 6085004
[TBL] [Abstract][Full Text] [Related]
14. Prevention of coronary platelet aggregation with a phosphodiesterase inhibitor RX-RA 69.
Machleidt C; Rose P; Mittmann U
Thromb Res; 1985 Mar; 37(5):595-604. PubMed ID: 2984803
[TBL] [Abstract][Full Text] [Related]
15. In vivo studies with the stabilized epoprostenol analogue taprostene. Effects on platelet functions and blood clotting.
Michel G; Seipp U
Arzneimittelforschung; 1990 Aug; 40(8):932-8. PubMed ID: 2242087
[TBL] [Abstract][Full Text] [Related]
16. The effect of prostacyclin (PGT2) on platelet behaviour. Thrombus formation in vivo and bleeding time.
Ubatuba FB; Moncada S; Vane JR
Thromb Haemost; 1979 Apr; 41(2):425-35. PubMed ID: 382434
[TBL] [Abstract][Full Text] [Related]
17. Activation of cGMP-stimulated phosphodiesterase by nitroprusside limits cAMP accumulation in human platelets: effects on platelet aggregation.
Dickinson NT; Jang EK; Haslam RJ
Biochem J; 1997 Apr; 323 ( Pt 2)(Pt 2):371-7. PubMed ID: 9163326
[TBL] [Abstract][Full Text] [Related]
18. 7-Bromo-1,5-dihydro-3,6-dimethylimidazo[2,1-b]quinazolin-2(3H)- one (Ro 15-2041), a potent antithrombotic agent that selectively inhibits platelet cyclic AMP-phosphodiesterase.
Muggli R; Tschopp TB; Mittelholzer E; Baumgartner HR
J Pharmacol Exp Ther; 1985 Oct; 235(1):212-9. PubMed ID: 2995647
[TBL] [Abstract][Full Text] [Related]
19. Influence of platelet volume on the ability of prostacyclin to inhibit platelet aggregation and the release reaction.
Jakubowski JA; Adler B; Thompson CB; Valeri CR; Deykin D
J Lab Clin Med; 1985 Feb; 105(2):271-6. PubMed ID: 3882862
[TBL] [Abstract][Full Text] [Related]
20. Potentiation of anti-aggregating activity of PGI2 by 7-ethoxycarbonyl-6,8-dimethyl-4-hydroxymethyl-1(2H)-phthalazinone (EG-626) in rabbit platelets in vitro.
Tanaka K; Harada Y; Iwata M; Katori M
Prostaglandins; 1980 Aug; 20(2):255-68. PubMed ID: 6997930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
